Literature DB >> 11104315

Anxiety as a predictor and outcome variable in the multimodal treatment study of children with ADHD (MTA).

J S March1, J M Swanson, L E Arnold, B Hoza, C K Conners, S P Hinshaw, L Hechtman, H C Kraemer, L L Greenhill, H B Abikoff, L G Elliott, P S Jensen, J H Newcorn, B Vitiello, J Severe, K C Wells, W E Pelham.   

Abstract

Initial moderator analyses in the Multimodal Treatment Study of Children with ADHD (MTA) suggested that child anxiety ascertained by parent report on the Diagnostic Interview Schedule for Children 2.3 (DISC Anxiety) differentially moderated the outcome of treatment. Left unanswered were questions regarding the nature of DISC Anxiety, the impact of comorbid conduct problems on the moderating effect of DISC Anxiety, and the clinical significance of DISC Anxiety as a moderator of treatment outcome. Thirty-three percent of MTA subjects met DSM-III-R criteria for an anxiety disorder excluding simple phobias. Of these, two-thirds also met DSM-III-R criteria for comorbid oppositional-defiant or conduct disorder whereas one-third did not, yielding an odds ratio of approximately two for DISC Anxiety, given conduct problems. In this context, exploratory analyses of baseline data suggest that DISC Anxiety may reflect parental attributions regarding child negative affectivity and associated behavior problems (unlike fearfulness), particularly in the area of social interactions, another core component of anxiety that is more typically associated with phobic symptoms. Analyses using hierarchical linear modeling (HLM) indicate that the moderating effect of DISC Anxiety continues to favor the inclusion of psychosocial treatment for anxious ADHD children irrespective of the presence or absence of comorbid conduct problems. This effect, which is clinically meaningful, is confined primarily to parent-reported outcomes involving disruptive behavior, internalizing symptoms, and inattention; and is generally stronger for combined than unimodal treatment. Contravening earlier studies, no adverse effect of anxiety on medication response for core ADHD or other outcomes in anxious or nonanxious ADHD children was demonstrated. When treating ADHD, it is important to search for comorbid anxiety and negative affectivity and to adjust treatment strategies accordingly.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11104315     DOI: 10.1023/a:1005179014321

Source DB:  PubMed          Journal:  J Abnorm Child Psychol        ISSN: 0091-0627


  31 in total

1.  Social phobia and separation anxiety symptoms in community and clinical samples of children and adolescents.

Authors:  S N Compton; A H Nelson; J S March
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2000-08       Impact factor: 8.829

Review 2.  Comorbidity in ADHD: implications for research, practice, and DSM-V.

Authors:  P S Jensen; D Martin; D P Cantwell
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1997-08       Impact factor: 8.829

3.  A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD.

Authors: 
Journal:  Arch Gen Psychiatry       Date:  1999-12

4.  Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of children with Attention-deficit/hyperactivity disorder.

Authors: 
Journal:  Arch Gen Psychiatry       Date:  1999-12

5.  Now you see it, now you don't: a comparison of traditional versus random-effects regression models in the analysis of longitudinal follow-up data from a clinical trial.

Authors:  C Nich; K Carroll
Journal:  J Consult Clin Psychol       Date:  1997-04

6.  Assessment and intervention for attention-deficit/hyperactivity disorder in the schools. Lessons from the MTA study.

Authors:  J Swanson; M Lerner; J March; F M Gresham
Journal:  Pediatr Clin North Am       Date:  1999-10       Impact factor: 3.278

7.  Medication treatment strategies in the MTA Study: relevance to clinicians and researchers.

Authors:  L L Greenhill; H B Abikoff; L E Arnold; D P Cantwell; C K Conners; G Elliott; L Hechtman; S P Hinshaw; B Hoza; P S Jensen; J S March; J Newcorn; W E Pelham; J B Severe; J M Swanson; B Vitiello; K Wells
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1996-10       Impact factor: 8.829

8.  The NIMH Diagnostic Interview Schedule for Children Version 2.3 (DISC-2.3): description, acceptability, prevalence rates, and performance in the MECA Study. Methods for the Epidemiology of Child and Adolescent Mental Disorders Study.

Authors:  D Shaffer; P Fisher; M K Dulcan; M Davies; J Piacentini; M E Schwab-Stone; B B Lahey; K Bourdon; P S Jensen; H R Bird; G Canino; D A Regier
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1996-07       Impact factor: 8.829

9.  Which boys respond to stimulant medication? A controlled trial of methylphenidate in boys with disruptive behaviour.

Authors:  E Taylor; R Schachar; G Thorley; H M Wieselberg; B Everitt; M Rutter
Journal:  Psychol Med       Date:  1987-02       Impact factor: 7.723

Review 10.  Comorbidity of attention-deficit/hyperactivity disorder with psychiatric disorder: an overview.

Authors:  S R Pliszka
Journal:  J Clin Psychiatry       Date:  1998       Impact factor: 4.384

View more
  53 in total

Review 1.  New treatments and approaches for attention deficit hyperactivity disorder.

Authors:  J H Newcorn
Journal:  Curr Psychiatry Rep       Date:  2001-04       Impact factor: 5.285

2.  Plus ça change....

Authors:  J Lexchin
Journal:  Can Fam Physician       Date:  2000-03       Impact factor: 3.275

3.  What have we learned about trial design from NIMH-funded pragmatic trials?

Authors:  John March; Helena C Kraemer; Madhukar Trivedi; John Csernansky; John Davis; Terence A Ketter; Ira D Glick
Journal:  Neuropsychopharmacology       Date:  2010-08-25       Impact factor: 7.853

4.  Does brief, clinically based, intensive multimodal behavior therapy enhance the effects of methylphenidate in children with ADHD?

Authors:  Saskia van der Oord; Pier J M Prins; Jaap Oosterlaan; Paul M G Emmelkamp
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-09-13       Impact factor: 4.785

5.  Anxiety modulates the relation between attention-deficit/hyperactivity disorder severity and working memory-related brain activity.

Authors:  Dennis van der Meer; Pieter J Hoekstra; Daan van Rooij; Anderson M Winkler; Hanneke van Ewijk; Dirk J Heslenfeld; Jaap Oosterlaan; Stephen V Faraone; Barbara Franke; Jan K Buitelaar; Catharina A Hartman
Journal:  World J Biol Psychiatry       Date:  2017-03-01       Impact factor: 4.132

6.  Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.

Authors:  Denis G Sukhodolsky; Lawrence Scahill; Kenneth D Gadow; L Eugene Arnold; Michael G Aman; Christopher J McDougle; James T McCracken; Elaine Tierney; Susan Williams White; Luc Lecavalier; Benedetto Vitiello
Journal:  J Abnorm Child Psychol       Date:  2007-08-03

Review 7.  The pharmacological management of childhood anxiety disorders: a review.

Authors:  Shauna P Reinblatt; Mark A Riddle
Journal:  Psychopharmacology (Berl)       Date:  2007-01-05       Impact factor: 4.530

8.  Managing ADHD in children, adolescents, and adults with comorbid anxiety in primary care.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

9.  Treatment of attention deficit hyperactivity disorder in children. Predictors of treatment outcome.

Authors:  Saskia van der Oord; P J M Prins; J Oosterlaan; P M G Emmelkamp
Journal:  Eur Child Adolesc Psychiatry       Date:  2007-09-14       Impact factor: 4.785

10.  Dopamine transporter genotype and stimulant side effect factors in youth diagnosed with attention-deficit/hyperactivity disorder.

Authors:  Reut Gruber; Ridha Joober; Natalie Grizenko; Bennett L Leventhal; Edwin H Cook; Mark A Stein
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-06       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.